{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:30Z","timestamp":1791308850202,"version":"4.3.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.vaccine.2010.02.006","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T09:27:14Z","timestamp":1266485234000},"page":"2999-3007","source":"Crossref","is-referenced-by-count":86,"title":["Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity"],"prefix":"10.1016","volume":"28","author":[{"given":"Michael","family":"Vaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Arthos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"May (19)","key":"10.1016\/j.vaccine.2010.02.006_bib1","first-page":"1915","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"October (15)","key":"10.1016\/j.vaccine.2010.02.006_bib2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"The New England Journal of Medicine"},{"issue":"February (9\u201310)","key":"10.1016\/j.vaccine.2010.02.006_bib3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0264-410X(02)00548-0","article-title":"Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs","volume":"21","author":"Hogarth","year":"2003","journal-title":"Vaccine"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2010.02.006_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nature Biotechnology"},{"issue":"Suppl. 3, May (31)","key":"10.1016\/j.vaccine.2010.02.006_bib5","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0264-410X(02)00164-0","article-title":"Overview of vaccine adjuvants: present and future","volume":"20","author":"Hunter","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.02.006_bib6","first-page":"213","article-title":"Some investigations into the mode of action of the water-in-mineral-oil emulsion antigen adjuvants","volume":"6","author":"Herbert","year":"1967","journal-title":"Proceedings of the International Symposium on Adjuvants of Immunity"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2010.02.006_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrmicro1681","article-title":"The perfect mix: recent progress in adjuvant research","volume":"5","author":"Guy","year":"2007","journal-title":"Nature Reviews Microbiology"},{"issue":"May (19)","key":"10.1016\/j.vaccine.2010.02.006_bib8","first-page":"473","article-title":"Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types","volume":"126","author":"Jarrett","year":"1990","journal-title":"The Veterinary Record"},{"issue":"6","key":"10.1016\/j.vaccine.2010.02.006_bib9","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000150171","article-title":"Bovine serological response to a recombinant BPV-1 major capsid protein vaccine","volume":"31","author":"Jin","year":"1990","journal-title":"Intervirology"},{"key":"10.1016\/j.vaccine.2010.02.006_bib10","first-page":"136","article-title":"Immunization against bovine papillomavirus infection","volume":"120","author":"Pilacinski","year":"1986","journal-title":"Ciba Foundation Symposium"},{"issue":"September (2)","key":"10.1016\/j.vaccine.2010.02.006_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.2910490224","article-title":"Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts","volume":"49","author":"Ghim","year":"1991","journal-title":"International Journal of Cancer"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2010.02.006_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Current Opinion in Biotechnology"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.02.006_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: ready for prime time?","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nature Reviews"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2010.02.006_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Current Opinion in Immunology"},{"issue":"August (15)","key":"10.1016\/j.vaccine.2010.02.006_bib15","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1128\/JVI.00562-08","article-title":"Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination","volume":"82","author":"Vaine","year":"2008","journal-title":"Journal of Virology"},{"issue":"June (12)","key":"10.1016\/j.vaccine.2010.02.006_bib16","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1128\/JVI.79.12.7933-7937.2005","article-title":"Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1","volume":"79","author":"Wang","year":"2005","journal-title":"Journal of Virology"},{"issue":"29\u201330","key":"10.1016\/j.vaccine.2010.02.006_bib17","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.vaccine.2008.04.073","article-title":"Heterologous HA DNA vaccine prime\u2013inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"June (1)","key":"10.1016\/j.vaccine.2010.02.006_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.virol.2006.02.032","article-title":"Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E","volume":"350","author":"Wang","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.02.006_bib19","series-title":"Current protocols in immunology","first-page":"1","article-title":"Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays","author":"Montefiori","year":"2004"},{"issue":"September (17)","key":"10.1016\/j.vaccine.2010.02.006_bib20","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1128\/JVI.00956-06","volume":"80","author":"Derby","year":"2006","journal-title":"Journal of Virology"},{"issue":"September (2)","key":"10.1016\/j.vaccine.2010.02.006_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.virol.2007.04.033","article-title":"A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120","volume":"366","author":"Crooks","year":"2007","journal-title":"Virology"},{"issue":"July (31)","key":"10.1016\/j.vaccine.2010.02.006_bib22","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1016\/j.vaccine.2007.12.060","article-title":"Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"issue":"March (5)","key":"10.1016\/j.vaccine.2010.02.006_bib23","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/JVI.80.5.2515-2528.2006","article-title":"Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1","volume":"80","author":"Moore","year":"2006","journal-title":"Journal of Virology"},{"issue":"April (7238)","key":"10.1016\/j.vaccine.2010.02.006_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nature07930","article-title":"Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals","volume":"458","author":"Scheid","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.vaccine.2010.02.006_bib25","doi-asserted-by":"crossref","first-page":"e1000171","DOI":"10.1371\/journal.ppat.1000171","article-title":"B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4","volume":"4","author":"Forsell","year":"2008","journal-title":"PLoS Pathogens"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2010.02.006_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.virol.2008.07.007","article-title":"Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses","volume":"380","author":"Wu","year":"2008","journal-title":"Virology"},{"issue":"August (16)","key":"10.1016\/j.vaccine.2010.02.006_bib27","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"Li","year":"2005","journal-title":"Journal of Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2010.02.006_bib28","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1128\/JVI.72.11.9092-9100.1998","article-title":"Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting","volume":"72","author":"Richmond","year":"1998","journal-title":"Journal of Virology"},{"issue":"May (9)","key":"10.1016\/j.vaccine.2010.02.006_bib29","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1128\/JVI.02173-08","article-title":"Preclinical studies of human immunodeficiency virus\/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia","volume":"83","author":"Zhao","year":"2009","journal-title":"Journal of Virology"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2010.02.006_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.virol.2009.05.039","article-title":"Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope","volume":"392","author":"Zolla-Pazner","year":"2009","journal-title":"Virology"},{"issue":"July (14)","key":"10.1016\/j.vaccine.2010.02.006_bib31","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1128\/JVI.02202-05","article-title":"Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1","volume":"80","author":"Gorny","year":"2006","journal-title":"Journal of Virology"},{"key":"10.1016\/j.vaccine.2010.02.006_bib32","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.str.2009.09.012","article-title":"Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens","volume":"17","author":"Burke","year":"2009","journal-title":"Structure"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2010.02.006_bib33","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nm1624","article-title":"Broad HIV-1 neutralization mediated by CD4-binding site antibodies","volume":"13","author":"Li","year":"2007","journal-title":"Nature Medicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T02:04:21Z","timestamp":1590631461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0264410X10001581"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.02.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}